This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

This study has been completed.
Information provided by (Responsible Party):
S*BIO Identifier:
First received: July 20, 2008
Last updated: April 19, 2012
Last verified: April 2012
This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with advanced myeloid malignancies; the second portion of the study is a Phase 2 study to define the efficacy and safety profile of single-agent SB1518 at the recommended dose in subjects with chronic idiopathic myelofibrosis (CIMF).

Condition Intervention Phase
Acute Myelogenous Leukemia Chronic Myelogenous Leukemia Chronic Myelomonocytic Leukemia Myelodysplastic Syndromes Myelofibrosis Drug: SB1518 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Resource links provided by NLM:

Further study details as provided by S*BIO:

Primary Outcome Measures:
  • Phase 1: To establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily in subjects with advanced myeloid malignancies [ Time Frame: Throughout the study ]
  • Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose. [ Time Frame: Throughout the study ]

Secondary Outcome Measures:
  • Assess the safety and tolerability of SB1518, administered once daily in subjects with advanced myeloid malignancies [ Time Frame: Throughout the study ]
  • Assess the pharmacokinetic and pharmacodynamic profile of SB1518 [ Time Frame: Throughout the study ]

Enrollment: 76
Study Start Date: August 2008
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: SB1518
    SB1518 taken orally daily for 28 consecutive days in a 28-day cycle

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • During the dose escalation phase: subjects with histologically confirmed myeloid malignancy who have failed standard therapies or are not candidates for palliative therapies. This includes the following:

    • Subjects with Acute Myelogenous Leukemia (AML)
    • Subjects with Chronic Myelogenous Leukemia (CML) in accelerated phase
    • Subjects with Chronic Myelogenous Leukemia (CML) in blast crisis
    • Subjects with high-risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    • Subjects with Advanced Myelofibrosis (MF)
    • In Phase 2, subjects with CIMF (as well as post ET/PV MF)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • All men of reproductive potential and women of child-bearing potential must agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists. Additionally, women of child-bearing potential must have a negative pregnancy test within 14 days prior to the first dose of study drug
  • Able to understand and willing to sign the informed consent form

Exclusion Criteria

  • Subjects with Chronic Myelogenous Leukemia (CML) in chronic phase;
  • Uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study;
  • Concurrent malignancy, except those subjects with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia are eligible for the study;
  • Known HIV-positive (such subjects are at increased risk of lethal infections when treated with potentially marrow-suppressive therapy);
  • Known active hepatitis A, B, or C;
  • Women who are pregnant or lactating.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00719836

United States, Illinois
The University of Chicago Hospitals
Chicago, Illinois, United States, 60637
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Principal Investigator: Srdan Verstovsek, M.D, Ph.D M.D. Anderson Cancer Center
Principal Investigator: H. Joachim Deeg, M.D Fred Hutchinson Cancer Center
Principal Investigator: Olatoyosi M. Odenike, M.D. The University of Chicago Hospitals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: S*BIO Identifier: NCT00719836     History of Changes
Other Study ID Numbers: SB1518-2007-001
Study First Received: July 20, 2008
Last Updated: April 19, 2012

Keywords provided by S*BIO:
Chronic Idiopathic Myelofibrosis
JAK2 Inhibitor

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Primary Myelofibrosis
Leukemia, Myeloid, Acute
Leukemia, Myelomonocytic, Chronic
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases processed this record on September 21, 2017